Skip to content

When you’re drowning in dropsIntervene early and rise above with iDose TR

A paradigm-changing technology

iDose TR is a procedural pharmaceutical that delivers prostaglandin analog therapy for the reduction of intraocular pressure in patients with open-angle glaucoma or ocular hypertension.1

24/7 adherence

First-of-its-kind anchored implant designed to deliver continuous drug therapy1,2

Handcrafted

Each iDose TR is individually fashioned through micro-scale design capabilities using biocompatible materials1

Controlled delivery

Proprietary membrane with nanoporous material to control drug elution while delivering therapy1,3

Designed to help reduce the flood of issues caused by drops1-6

View of the applicator's parts with 'for-scale' reference Close up of the applicator's tip components

Replace a flood of drops with iDose TR2

Actual size of implant is 1.8mm x 0.5 mm2 – immensely smaller than a single eye drop.

iDOSE TR EFFICACY

GLAUKOS SUPPORT

Ready to hear more?

Contact a representative to request more info.

References: 1. iDose TR (travoprost intracameral implant) 75 mcg Prescribing Information. Glaukos Corporation. 2023. 2. Berdahl JP, Sarkisian SR Jr, Ang RE, et al. Efficacy and safety of the travoprost intraocular implant in reducing topical IOP‐lowering medication burden in patients with open‐angle glaucoma or ocular hypertension. Drugs. 2024;84(1):83-97. 3. iDose TR Phase 3 Clinical Trials, data on file, Glaukos Corporation. 4. Teymoorian S, Kaur J. Travoprost intracameral implant in eyes with glaucoma or ocular hypertension: early short-term real-world outcomes. Clin Ophthalmol. 2025;19:157-166. 5. Economic burden worsens for glaucoma patients. Review of Optometry. Published March 24, 2021. Accessed August 7, 2025. https://www.reviewofoptometry.com/article/econcmic-burden-worsens-for-glaucoma-patients 6. Nordstrom BL, Friedman DS, Mozaffair E, Quigley HA, Walker AM. Persistence and adherence with topical glaucoma therapy. Am J Ophthalmol. 2005;140(4):598-606.

Important Safety Information

Dosage and Administration

For ophthalmic intracameral administration. The intracameral administration should be carried out under standard aseptic conditions.

Contraindications

iDose TR is contraindicated in patients with active or suspected ocular or periocular infections, patients with corneal endothelial cell dystrophy (e.g., Fuch’s Dystrophy, corneal guttatae), patients with prior corneal transplantation, or endothelial cell transplants (e.g., Descemet’s Stripping Automated Endothelial Keratoplasty [DSAEK]), patients with hypersensitivity to travoprost or to any other components of the product.

Warnings and Precautions

iDose TR should be used with caution in patients with narrow angles or other angle abnormalities. Monitor patients routinely to confirm the location of the iDose TR at the site of administration. Increased pigmentation of the iris can occur. Iris pigmentation is likely to be permanent.

Adverse Reactions

In controlled studies, the most common ocular adverse reactions reported in 2% to 6% of patients were increases in intraocular pressure, iritis, dry eye, visual field defects, eye pain, ocular hyperaemia, and reduced visual acuity.

Indications and Usage

iDose TR (travoprost intracameral implant) is indicated for the reduction of intraocular pressure (IOP) in patients with open-angle glaucoma (OAG) or ocular hypertension (OHT).

Please see full Prescribing Information.

You are encouraged to report all side effects to the FDA. Visit www.fda.gov/medwatch, or call 1-800-FDA-1088. You may also call Glaukos at 1-888-404-1644.

The information contained in this site is intended for US healthcare professionals only.

YES, I AM A US HEALTHCARE PROFESSIONAL NO, I AM NOT A US HEALTHCARE PROFESSIONAL

Request more info

"*" indicates required fields

*Required.

By entering this information, you confirm that you are at least 18 years old and that you have read and accept the terms of our Privacy Policy. Glaukos will use the information you provide on this form to provide product updates and other promotional materials. Should you change your mind, you may unsubscribe using the link in the footer of any email you receive from us.

Stay connected

Sign up to receive the latest information about iDose® TR!

"*" indicates required fields

This field is for validation purposes and should be left unchanged.
*Required.

Glaukos will use the information you provide on this form to get in touch with you.

By entering this information, you confirm that you are at least 18 years old and that you have read and accept the terms of our Privacy Policy. Glaukos will use the information you provide on this form to provide product updates and other promotional materials. Should you change your mind, you may unsubscribe using the link in the footer of any email you receive from us.